Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation

Navigating SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Incyte Corporation and Geron Corporation from 2014 to 2023. Over this period, Incyte's SG&A expenses surged by approximately 600%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Geron Corporation's expenses grew by around 300%, indicating a more conservative approach.

Key Insights

• Incyte Corporation: By 2023, Incyte's SG&A expenses reached over 1.16 billion, a testament to its strategic investments in research and development.
• Geron Corporation: Despite a more modest increase, Geron's expenses peaked at nearly 69 million in 2023, highlighting its focus on maintaining lean operations.

This financial narrative underscores the diverse strategies employed by biotech firms in managing operational costs while striving for market leadership.